Galderma 
Created in 1981, Galderma is a joint venture between Nestlé and L'Oréal.
Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma’s important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, over-the-counter drugs and aesthetic and corrective solutions) contribute to maintaining its strong leadership in dermatology.
Galderma is interested in acquiring or in-licensing products for corrective dermatology and for the treatment of acne, rosacea, onychomycosis, psoriasis, seborrheic dermatitis, atopic dermatitis, other inflammatory dermatoses, non-melanoma skin cancer, viral warts, and pigmentary disorders.
Mr Art Clapp
Director - US Business Development
Gerson Lehrman Group
GLG Research partners with organizations seeking efficient, targeted connections to insight.
Our Healthcare Practice provides you with access to expert insights on issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors. GLG works with:
- 9 of the top 10 pharmaceutical and biotechnology companies
- More than 80,000 experts from across the entire healthcare industry including physicians, researchers, scientists, payors, and healthcare industry executives
- 7 out of the top 10 global medical equipment companies
- Over 300,000 experts from all sectors, including former C-level operating executives, ex-top-tier strategy consultants and thought leaders from around the world
Ms Jackie Ross
Vice President
Mrs Jacquelyn Nicholson
Vice President, Life Sciences
Mr Craig Farrell
Vice President, Business DevelopmentMr Kiva Kolstein
Senior Vice President - Head of Corporate and Life Sciences Business Development
GfK Bridgehead
GfK Bridgehead is a global strategic healthcare consultancy that specializes in pricing and reimbursement, opportunity assessment, market access strategy, health economics, transaction support, valuation and due diligence.
Preferred partner for many major companies in the pharmaceutical, medical device, diagnostic and financial sectors.
Respected for bringing payer insights into R&D, portfolio, business development, commercialization and lifecycle strategies.
Renowned for qualitative and quantitative research capabilties.
A truly global organization, able to draw upon the expertise of 500 healthcare experts in more than 100 countries.
Ms Sasha Richardson
Vice President, Strategic Market Access Consulting
